IRINOTECAN MEDAC 20 mg/ml clinical trials

PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients with resectable borderline pancreatic adenocarcinoma.

This study looks at new ways to treat a specific type of pancreatic cancer that can be operated on. We're testing if personalising chemotherapy based on a patient's genes can improve treatment results and help people live longer and healthier lives.